Skip to main content
Login | Suomeksi | På svenska | In English

64Cu production, ligands and biomedical applications

Show simple item record

dc.date.accessioned 2010-11-25T12:04:47Z und
dc.date.accessioned 2017-11-06T11:59:50Z
dc.date.available 2010-11-25T12:04:47Z und
dc.date.available 2017-11-06T11:59:50Z
dc.date.issued 2006-11-27
dc.identifier.uri http://hdl.handle.net/10138/21158
dc.publisher Helsingin yliopisto fi
dc.publisher Helsingfors universitet sv
dc.publisher University of Helsinki en
dc.title 64Cu production, ligands and biomedical applications en
ethesis.discipline Radiochemistry en
ethesis.discipline Radiokemia fi
ethesis.discipline Radiokemi sv
ethesis.discipline.URI http://data.hulib.helsinki.fi/id/A18c84da-ebaf-4d10-9239-812b258a1067
ethesis.department.URI http://data.hulib.helsinki.fi/id/c2dd677c-da9c-4011-94b0-27b1585ac1cb
ethesis.department Kemiska institutionen sv
ethesis.department Department of Chemistry en
ethesis.department Kemian laitos fi
ethesis.faculty Matematisk-naturvetenskapliga fakulteten sv
ethesis.faculty Matemaattis-luonnontieteellinen tiedekunta fi
ethesis.faculty Faculty of Science en
ethesis.faculty.URI http://data.hulib.helsinki.fi/id/8d59209f-6614-4edd-9744-1ebdaf1d13ca
ethesis.university.URI http://data.hulib.helsinki.fi/id/50ae46d8-7ba9-4821-877c-c994c78b0d97
ethesis.university Helsingfors universitet sv
ethesis.university University of Helsinki en
ethesis.university Helsingin yliopisto fi
dct.creator Makkonen-Craig, Stewart
dct.issued 2006
dct.language.ISO639-2 eng
dct.abstract 64Cu (Iβ+ = 17%, Iβ− = 39%, IEC = 43%) is an important emerging biomedical radionuclide that is suitable for labelling a wide range of radiopharmaceuticals for PET imaging, as well as systemic or local radioimmunotherapy of tumours. Its positron energy spectrum is comparable with that of 18F, allowing high spatial resolution in PET imaging. Its intermediate half-life (12.7 h) permits PET evaluation of slow biochemical pathways, such as protein and peptide interactions with cellular targets, and distribution to satellite imaging and therapy centres. The optimum production route for radiochemically-pure, carrier-free 64Cu is via the reaction 64Ni(p,n) at 12 → 9 MeV followed by anion exchange chromatography. Biomedical applications follow three principal strategies: (i) direct application of 64Cu as a biological tracer, (ii) complexing with redox sensitive ligands (e.g. bisthiosemicarbazones) that release 64Cu upon reduction in hypoxic cells, and (iii) coordination with bifunctional ligands (e.g. tetraaza macrocycles) that covalently bond to intact antibodies, antibody fragments, peptides, peptide analogues or shell cross-linked nanoparticles for targeting receptors expressed by tumours. en
dct.language en
ethesis.language.URI http://data.hulib.helsinki.fi/id/languages/eng
ethesis.language English en
ethesis.language englanti fi
ethesis.language engelska sv
ethesis.supervisor Helariutta, Kerttuli
ethesis.thesistype pro gradu-avhandlingar sv
ethesis.thesistype pro gradu -tutkielmat fi
ethesis.thesistype master's thesis en
ethesis.thesistype.URI http://data.hulib.helsinki.fi/id/thesistypes/mastersthesis
dct.identifier.urn URN:NBN:fi-fe20061768
dc.type.dcmitype Text
dct.rights This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited. en
dct.rights Publikationen är skyddad av upphovsrätten. Den får läsas och skrivas ut för personligt bruk. Användning i kommersiellt syfte är förbjuden. sv
dct.rights Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty. fi

Files in this item

Files Size Format View
64cuprod.pdf 1.901Mb PDF

This item appears in the following Collection(s)

Show simple item record